According to GlobalData’s medical device pipeline database, ten Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) devices are in various stages of development globally. GlobalData’s report Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, four are in active development, while the remaining six are in an inactive stage of development. There are two products in the early stages of development, and the remaining two are in the late stages of development.
Cardiovascular Devices are used to detect and treat heart and circulatory system related diseases. Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) is used to treat cardiac arrhythmia by sending electrical impulses to the heart. Cardiac Resynchronisation Therapy – Defibrillators (CRT-D) is implanted in the chest and uses an Implantable Cardioverter Defibrillator (ICD) to improve the coordination of the heart rhythm. It consists of three parts: a generator, a lead, and a receiver. The generator is the battery-powered part of the device. The lead is a thin wire that is inserted into the heart. The receiver is a small computer that is implanted in the chest.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) devices. Overall, most of these Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) pipeline devices are being developed by private entities.
Key players involved in the active development of Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) include Boston Scientific, MicroPort Scientific, NewPace, Suzhou Singular Medical, IRadimed, Johns Hopkins University, Mayo Clinic and MicroPort CRM.
For a complete picture of the developmental pipeline for Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.